市场调查报告书

即时检验(POC)检验行业分析报告:产品/技术/处方/应用/最终用途/区域前景/应用潜力/价格趋势/竞争性市场份额和预测(2020-2026)

Point of Care Testing Market Size By Product, By Technology, By Prescription, By Application, By End-use, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026

出版商 Global Market Insights Inc. 商品编码 969427
出版日期 内容资讯 英文 400 Pages
商品交期: 2-3个工作天内
价格
即时检验(POC)检验行业分析报告:产品/技术/处方/应用/最终用途/区域前景/应用潜力/价格趋势/竞争性市场份额和预测(2020-2026) Point of Care Testing Market Size By Product, By Technology, By Prescription, By Application, By End-use, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026
出版日期: 2020年11月05日内容资讯: 英文 400 Pages
简介

全球护理点(POC)测试市场是医疗保健和医疗设备领域最重要的垂直市场之一,预计在未来几年内将显著增长。由于全球慢性病的发病率以及老年人口的迅速增加,对先进诊断方法和技术的需求正在增加。

本报告调查并分析了全球护理点(POC)检查市场,并分析了市场概况,按细分/地区划分的市场趋势,市场规模趋势和预测,市场推动者和障碍。它提供系统的信息,例如市场前景,竞争状况和主要公司的概况。

目录

第1章调查方法和范围

  • 市场定义
  • 市场估计和预测参数
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 预测参数
  • 数据验证
  • 数据源
    • 小学
    • 中学

第2章执行摘要

  • 护理点(POC)检验市场的全方位概述
    • 业务趋势
    • 产品趋势
    • 技术趋势
    • 处方趋势
    • 应用趋势
    • 最终使用趋势
    • 区域趋势

第3章现场检查(POC)检查行业的考虑

  • 行业细分
  • 行业状况
  • 行业影响因素
    • 生长因子
    • 行业中的潜在风险和挑战
  • 增长潜力分析
    • 副产品
    • 技术
    • 根据处方
    • 按应用
    • 最终用途
  • COVID-19的影响分析
  • 价格分析:按心脏标记
  • 监管状态
  • 技术状况
  • 公司股份分析
    • 全球市场份额分析
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 全球市场份额分析:按设置/应用
  • 公司的全球市场份额分析:按设置/应用
    • F. Hoffmann-La Roche Ltd
    • 雅培
    • 约翰逊和约翰逊
    • 西门子股份公司
    • 背屈
  • 波特分析
  • 竞争形势
    • 公司矩阵分析
  • PESTEL分析

第4章护理点(POC)检验市场:按产品

  • 主要细分市场的趋势
  • 血糖监测
    • 市场规模:按地区
    • 称重仪器
    • 柳叶刀
  • 心血管代谢检查产品
    • 市场规模:按地区
    • 心脏标志物测试产品
    • 血气/电解质测试产品
    • HBA1C测试产品
  • 传染病检查产品
    • 市场规模:按地区
    • 流感检测产品
    • 艾滋病检查产品
    • 丙型肝炎测试产品
    • 性感染(STD)测试产品
    • 医疗感染(HAI)测试产品
    • 呼吸道感染检查产品
    • 热带病检查产品
    • 其他传染病检查产品
  • 凝血测试产品
    • 市场规模:按地区
    • PT/INR测试产品
    • 活化凝血时间(ACT/APTT)测试产品
  • 怀孕和生育能力测试产品
    • 市场规模:按地区
    • 验孕产品
    • 生育力测试产品
  • 肿瘤/癌标志物检查商品
  • 尿液检查检查产品
  • 胆固醇测试产品
  • 血液检查产品
  • 药物滥用(DoA)测试产品
  • 粪便潜伏期测试产品
  • 其他产品

第5章即时医疗点(POC)检验市场:按技术

  • 主要细分市场的趋势
  • 横向流动分析
    • 市场规模:按地区
  • 浸油杆
  • 微流体
  • 分子诊断
  • 免疫学检查
  • 聚集测定
  • 流经
  • 固相
  • 生物传感器

第6章护理点(POC)检验市场:通过处方

  • 主要细分市场的趋势
  • OTC检查
    • 市场规模:按地区
  • 基于处方的检查

第7章即时医疗点(POC)检验市场:通过应用

  • 主要细分市场的趋势
  • 心血管代谢测试
    • 市场规模:按地区
  • 传染病检查
  • 肾脏检查
  • 药物滥用(DoA)测试
  • 血糖测试
  • 验孕
  • 癌症生物标志物测试
  • 其他应用

第8章护理点(POC)检验市场:最终用途

  • 主要细分市场的趋势
  • 医院
    • 市场规模:按地区
  • 诊断中心
  • 研究
  • 家庭医疗
  • 其他

第9章即时医疗点(POC)检验市场:按地区

  • 主要区域趋势
  • 北美
    • 市场规模:按国家
    • 市场规模:按产品
    • 市场规模:按技术
    • 市场规模:按处方
    • 市场规模:按应用
    • 市场规模:按最终用途
    • 美国
    • 加拿大
  • 欧洲
    • 市场规模:按国家
    • 市场规模:按产品
    • 市场规模:按技术
    • 市场规模:按处方
    • 市场规模:按应用
    • 市场规模:按最终用途
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
  • 亚太地区
    • 市场规模:按国家
    • 市场规模:按产品
    • 市场规模:按技术
    • 市场规模:按处方
    • 市场规模:按应用
    • 市场规模:按最终用途
    • 中国
    • 日本
    • 印度
    • 澳大利亚
  • 拉丁美洲
    • 市场规模:按国家
    • 市场规模:按产品
    • 市场规模:按技术
    • 市场规模:按处方
    • 市场规模:按应用
    • 市场规模:按最终用途
    • 巴西
    • 墨西哥
  • 中东和非洲
    • 市场规模:按国家
    • 市场规模:按产品
    • 市场规模:按技术
    • 市场规模:按处方
    • 市场规模:按应用
    • 市场规模:按最终用途
    • 南非
    • 沙特阿拉伯

第10章公司简介

  • Abaxis, Inc.
  • Abbott Laboratories
  • Accubiotech Co, Ltd.
  • ACON Laboratories, Inc.
  • Becton, Dickinson and Company
  • Biolytical Laboratories
  • BioMrieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation (HemoCue)
  • Dexcom, Inc
  • Dragerwerk Ag & Co
  • LifeScan IP Holdings, LLC
  • Medtronic
  • Meridian Bioscience, Inc
  • Nova Biomedical
  • Orasure Technologies, Inc
  • F Hoffmann-La Roche Ltd
  • Siemens Healthineers
  • Sysmex Corporation
  • Trinity Biotech
目录
Product Code: 3086

Title:
Point of Care Testing Market Size By Product (Glucose Monitoring, Cardiometabolic Testing, Infectious Disease Testing, Coagulation Testing, Pregnancy and Fertility Testing, Tumor/Cancer Marker Testing, Urinalysis Testing, Cholesterol Testing, Hematology Testing, Drugs-of-Abuse Testing, Fecal Occult Testing), By Technology (Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays, Agglutination Assays, Flow-Through, Solid Phase, Biosensors), By Prescription (OTC Testing, Prescription-based Testing), By Application (Cardio Metabolic Testing, Infectious Disease Testing, Nephrology Testing, Drug-of-Abuse (DoA) Testing, Blood Glucose Testing, Pregnancy Testing, Cancer Biomarker Testing), By End-use (Hospitals, Diagnostic Centers, Research Laboratories, Home-Care Settings), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026.

One of the most crucial verticals within the healthcare and medical devices space, global point of care testing market is slated to witness exponential growth over the next few years. The rapid increase in occurrence of chronic diseases and a large geriatric population across the globe has augmented the need for advanced diagnostic procedures and technologies.

In terms of the product landscape, global point of care testing industry is segmented into glucose monitoring, infectious diseases testing products, cardiometabolic testing products, coagulation testing products, tumor & cancer marker testing products, pregnancy & fertility testing products, drug-of-abuse testing products, hematology testing products, and cholesterol testing products.

Cardiometabolic testing market size was pegged at USD 2.5 billion in 2019. The test provides a clinically relevant evaluation to help identify a patient's risk for cardiovascular inflammation, progression towards type 2 diabetes (pre-diabetes), and atherosclerotic cardiovascular disease (ASCVD).

Considering the technology, global point of care testing market is bifurcated into lateral flow assays, biosensors, dipsticks, flow-through, microfluidics, immunoassays, molecular diagnostics, agglutination assays, and solid phase. The biosensors technology segment is projected to be worth more than US$11.8 billion by 2026.

On the basis of prescription, global point of care testing industry is divided into OTC testing and prescription based testing. The prescription based testing segment is poised to grow at a CAGR of over 7.4% through 2026.

The market is classified into cardiometabolic testing, nephrology testing, infectious disease testing, blood glucose testing, drug-of-abuse testing, cancer biomarker testing, and pregnancy testing based on applications. Blood glucose testing application segment accounted for more than 42.2% revenue share of global point of care testing market during 2019 and is likely to witness notable growth by 2026.

Blood glucose testing is an important procedure that measures glucose levels in the blood. Glucose is a type of sugar which is the main source of energy for the human body. Too little or too much glucose in the blood can lead to numerous critical conditions and complications. High blood glucose levels, also known as hyperglycemia, can indicate diabetes that can further increase the risk of heart diseases, kidney failure, blindness, and other complications. On the other hand, low blood glucose levels or hypoglycemia can cause major health problems such as brain damage.

Hospitals, research laboratories, diagnostic centers, and homecare settings are among the different end-users of point of care testing products. Global point of care testing industry size from home care settings is estimated to reach an annual valuation of over US$10.1 billion by 2026. This can be attributed to growing adoption of different diagnostic and testing products among consumers in homecare settings due to convenience and ease-of-use.

From a regional point of view, Latin America captured over 5.6% revenue share of global point of care market testing in 2019 and will grow substantially by 2026. The point of care testing industry in Middle East and Africa is likely to witness a healthy CAGR of nearly 7.7% through the same period.

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definitions
  • 1.2 Base estimates & working
    • 1.2.1 North America
    • 1.2.2 Europe
    • 1.2.3 Asia Pacific
    • 1.2.4 Latin America
    • 1.2.5 Middle East & Africa
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data Sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Point of care testing industry 360 degree synopsis, 2015-2026
    • 2.1.1 Business trends
    • 2.1.2 Product trends
    • 2.1.3 Technology trends
    • 2.1.4 Prescription trends
    • 2.1.5 Application trends
    • 2.1.6 End-use trends
    • 2.1.7 Regional trends

Chapter 3 Point of Care Testing Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2015 - 2026
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Upward trend in disease prevalence among developing countries
      • 3.3.1.2 Surging number of pathology labs and services equipped with advanced diagnostic equipment in North America
      • 3.3.1.3 Technological advancements
      • 3.3.1.4 Increasing R&D investment
      • 3.3.1.5 Growing geriatric population base globally
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 High cost of product development
  • 3.4 Growth potential analysis
    • 3.4.1 By product
    • 3.4.2 By technology
    • 3.4.3 By prescription
    • 3.4.4 By application
    • 3.4.5 By end-use
  • 3.5 COVID-19 impact analysis
  • 3.6 Pricing analysis, by cardiac markers, 2019
  • 3.7 Regulatory landscape
  • 3.8 Technology landscape
  • 3.9 Company share analysis, 2019
    • 3.9.1 Global market share analysis, 2019
    • 3.9.2 North America
    • 3.9.3 Europe
    • 3.9.4 Asia Pacific
    • 3.9.5 Latin America
    • 3.9.6 Middle East and Africa
  • 3.10 Global market share analysis, by settings and application, 2019
  • 3.11 Company global market share analysis, by setting and application, 2019
    • 3.11.1 F. Hoffmann-La Roche Ltd
    • 3.11.2 Abbott
    • 3.11.3 Johnson and Johnson
    • 3.11.4 Siemens AG
    • 3.11.5 Abaxis
  • 3.12 Porter's analysis
  • 3.13 Competitive landscape, 2019
    • 3.13.1 Company matrix analysis
  • 3.14 PESTEL analysis

Chapter 4 Point of Care Testing Market, By Product

  • 4.1 Key segment trends
  • 4.2 Glucose monitoring
    • 4.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.2.2 Strips
      • 4.2.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.2.3 Meters
      • 4.2.3.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.2.4 Lancets
      • 4.2.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.3 Cardiometabolic testing products
    • 4.3.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.3.2 Cardiac marker testing products
      • 4.3.2.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.2 High-sensitivity troponin I (hsTnl)
        • 4.3.2.2.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.3 Brain natriuretic peptide (BNP)
        • 4.3.2.3.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.4 D-dimer
        • 4.3.2.4.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.5 Creatine kinase-MB (CK-MB)
        • 4.3.2.5.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.6 Myoglobin
        • 4.3.2.6.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.7 Others
        • 4.3.2.7.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.3.3 Blood Gas/Electrolytes testing products
      • 4.3.3.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.3.4 HBA1C testing products
      • 4.3.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.4 Infectious disease testing products
    • 4.4.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.2 Influenza testing products
      • 4.4.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.3 HIV testing products
      • 4.4.3.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.4 Hepatitis C testing products
      • 4.4.4.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.5 Sexually transmitted disease (STD) testing products
      • 4.4.5.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.6 Healthcare-associated Infection (HAI) testing products
      • 4.4.6.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.7 Respiratory infection testing products
      • 4.4.7.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.8 Tropical disease testing products
      • 4.4.8.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.9 Other infectious diseases testing products
      • 4.4.9.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.5 Coagulation testing products
    • 4.5.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.5.2 PT/INR testing products
      • 4.5.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.5.3 Activated clotting time (ACT/APTT) testing products
      • 4.5.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.6 Pregnancy and fertility testing products
    • 4.6.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.6.2 Pregnancy testing products
      • 4.6.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.6.3 Fertility testing products
      • 4.6.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.7 Tumor/Cancer marker testing products
    • 4.7.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.8 Urinalysis testing products
    • 4.8.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.9 Cholesterol testing products
    • 4.9.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.10 Hematology testing products
    • 4.10.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.11 Drug-of-Abuse (DoA) testing products
    • 4.11.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.12 Fecal occult testing products
    • 4.12.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.13 Other products
    • 4.13.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 5 Point of Care Testing Market, By Technology

  • 5.1 Key segment trend
  • 5.2 Lateral flow assays
    • 5.2.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.3 Dipsticks
    • 5.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.4 Microfluidics
    • 5.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.5 Molecular diagnostics
    • 5.5.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.6 Immunoassays
    • 5.6.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.7 Agglutination assays
    • 5.7.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.8 Flow-Through
    • 5.8.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.9 Solid phase
    • 5.9.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.10 Biosensors
    • 5.10.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 6 Point of Care Testing Market, By Prescription

  • 6.1 Key segment trend
  • 6.2 OTC testing
    • 6.2.1 Market size, by region, 2015 - 2026 (USD Million)
  • 6.3 Prescription-based testing
    • 6.3.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 7 Point of Care Testing Market, By Application

  • 7.1 Key segment trend
  • 7.2 Cardio metabolic testing
    • 7.2.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.3 Infectious disease testing
    • 7.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.4 Nephrology testing
    • 7.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.5 Drug-of-Abuse (DoA) testing
    • 7.5.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.6 Blood glucose testing
    • 7.6.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.7 Pregnancy testing
    • 7.7.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.8 Cancer biomarker testing
    • 7.8.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.9 Other applications
    • 7.9.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 8 Point of Care Testing Market, By End-use

  • 8.1 Key segment trend
  • 8.2 Hospitals
    • 8.2.1 Market size, by region, 2015 - 2026 (USD Million)
  • 8.3 Diagnostic centers
    • 8.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 8.4 Research laboratories
    • 8.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 8.5 Home-care settings
    • 8.5.1 Market size, by region, 2015 - 2026 (USD Million)
  • 8.6 Others
    • 8.6.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 9 Point of Care Testing Market, By Region

  • 9.1 Key regional trends
  • 9.2 North America
    • 9.2.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.2.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.2.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.2.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.2.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.2.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.2.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.2.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.2.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.2.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.2.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.2.7 U.S.
      • 9.2.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.2.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.2.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.2.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.2.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.2.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.2.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.2.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.2.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.2.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.2.8 Canada
      • 9.2.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.2.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.2.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.2.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.2.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.2.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.2.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.2.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.2.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.2.8.5 Market size, by end-use, 2015 - 2026 (USD Million)
  • 9.3 Europe
    • 9.3.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.3.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.3.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.3.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.3.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.3.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.3.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.3.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.3.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.3.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.3.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.7 Germany
      • 9.3.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.8 UK
      • 9.3.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.8.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.9 France
      • 9.3.9.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.9.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.9.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.9.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.9.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.9.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.9.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.9.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.9.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.9.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.10 Spain
      • 9.3.10.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.10.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.10.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.10.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.10.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.10.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.10.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.10.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.10.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.10.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.11 Italy
      • 9.3.11.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.11.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.11.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.11.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.11.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.11.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.11.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.11.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.11.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.11.5 Market size, by end-use, 2015 - 2026 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.4.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.4.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.4.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.4.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.4.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.4.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.4.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.4.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.4.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.4.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.4.7 China
      • 9.4.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.4.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.4.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.4.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.4.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.4.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.4.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.4.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.4.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.4.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.4.8 Japan
      • 9.4.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.4.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.4.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.4.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.4.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.4.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.4.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.4.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.4.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.4.8.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.4.9 India
      • 9.4.9.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.4.9.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.4.9.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.4.9.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.4.9.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.4.9.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.4.9.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.4.9.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.4.9.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.4.9.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.4.10 Australia
      • 9.4.10.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.4.10.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.4.10.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.4.10.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.4.10.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.4.10.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.4.10.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.4.10.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.4.10.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.4.10.5 Market size, by end-use, 2015 - 2026 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.5.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.5.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.5.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.5.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.5.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.5.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.5.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.5.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.5.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.5.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.5.7 Brazil
      • 9.5.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.5.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.5.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.5.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.5.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.5.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.5.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.5.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.5.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.5.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.5.8 Mexico
      • 9.5.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.5.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.5.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.5.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.5.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.5.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.5.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.5.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.5.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.5.8.5 Market size, by end-use, 2015 - 2026 (USD Million)
  • 9.6 Middle East and Africa
    • 9.6.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.6.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.6.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.6.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.6.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.6.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.6.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.6.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.6.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.6.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.6.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.6.7 South Africa
      • 9.6.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.6.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.6.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.6.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.6.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.6.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.6.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.6.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.6.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.6.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.6.8 Saudi Arabia
      • 9.6.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.6.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.6.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.6.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.6.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.6.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.6.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.6.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.6.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.6.8.5 Market size, by end-use, 2015 - 2026 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Competitive dashboard
  • 10.2 Abaxis, Inc.
    • 10.2.1 Business overview
    • 10.2.2 Financial data
    • 10.2.3 Product landscape
    • 10.2.4 Strategic outlook
    • 10.2.5 SWOT analysis
  • 10.3 Abbott Laboratories
    • 10.3.1 Business overview
    • 10.3.2 Financial data
    • 10.3.3 Product landscape
    • 10.3.4 Strategic outlook
    • 10.3.5 SWOT analysis
  • 10.4 Accubiotech Co, Ltd.
    • 10.4.1 Business overview
    • 10.4.2 Financial data
    • 10.4.3 Product landscape
    • 10.4.4 Strategic outlook
    • 10.4.5 SWOT analysis
  • 10.5 ACON Laboratories, Inc.
    • 10.5.1 Business overview
    • 10.5.2 Financial data
    • 10.5.3 Product landscape
    • 10.5.4 Strategic outlook
    • 10.5.5 SWOT analysis
  • 10.6 Becton, Dickinson and Company
    • 10.6.1 Business overview
    • 10.6.2 Financial data
    • 10.6.3 Product landscape
    • 10.6.4 Strategic outlook
    • 10.6.5 SWOT analysis
  • 10.7 Biolytical Laboratories
    • 10.7.1 Business overview
    • 10.7.2 Financial data
    • 10.7.3 Product landscape
    • 10.7.4 Strategic outlook
    • 10.7.5 SWOT analysis
  • 10.8 BioMrieux SA
    • 10.8.1 Business overview
    • 10.8.2 Financial data
    • 10.8.3 Product landscape
    • 10.8.4 Strategic outlook
    • 10.8.5 SWOT analysis
  • 10.9 Bio-Rad Laboratories, Inc.
    • 10.9.1 Business overview
    • 10.9.2 Financial data
    • 10.9.3 Product landscape
    • 10.9.4 Strategic outlook
    • 10.9.5 SWOT analysis
  • 10.10 Danaher Corporation (HemoCue)
    • 10.10.1 Business overview
    • 10.10.2 Financial data
    • 10.10.3 Product landscape
    • 10.10.4 Strategic outlook
    • 10.10.5 SWOT analysis
  • 10.11 Dexcom, Inc
    • 10.11.1 Business overview
    • 10.11.2 Financial data
    • 10.11.3 Product landscape
    • 10.11.4 Strategic outlook
    • 10.11.5 SWOT analysis
  • 10.12 Dragerwerk Ag & Co
    • 10.12.1 Business overview
    • 10.12.2 Financial data
    • 10.12.3 Product landscape
    • 10.12.4 Strategic outlook
    • 10.12.5 SWOT analysis
  • 10.13 LifeScan IP Holdings, LLC
    • 10.13.1 Business overview
    • 10.13.2 Financial data
    • 10.13.3 Product landscape
    • 10.13.4 Strategic outlook
    • 10.13.5 SWOT analysis
  • 10.14 Medtronic
    • 10.14.1 Business overview
    • 10.14.2 Financial data
    • 10.14.3 Product landscape
    • 10.14.4 Strategic outlook
    • 10.14.5 SWOT analysis
  • 10.15 Meridian Bioscience, Inc
    • 10.15.1 Business overview
    • 10.15.2 Financial data
    • 10.15.3 Product landscape
    • 10.15.4 Strategic outlook
    • 10.15.5 SWOT analysis
  • 10.16 Nova Biomedical
    • 10.16.1 Business overview
    • 10.16.2 Financial data
    • 10.16.3 Product landscape
    • 10.16.4 Strategic outlook
    • 10.16.5 SWOT analysis
  • 10.17 Orasure Technologies, Inc
    • 10.17.1 Business overview
    • 10.17.2 Financial data
    • 10.17.3 Product landscape
    • 10.17.4 Strategic outlook
    • 10.17.5 SWOT analysis
  • 10.18 F Hoffmann-La Roche Ltd
    • 10.18.1 Business overview
    • 10.18.2 Financial data
    • 10.18.3 Product landscape
    • 10.18.4 Strategic outlook
    • 10.18.5 SWOT analysis
  • 10.19 Siemens Healthineers
    • 10.19.1 Business overview
    • 10.19.2 Financial data
    • 10.19.3 Product landscape
    • 10.19.4 Strategic outlook
    • 10.19.5 SWOT analysis
  • 10.20 Sysmex Corporation
    • 10.20.1 Business overview
    • 10.20.2 Financial data
    • 10.20.3 Product landscape
    • 10.20.4 Strategic outlook
    • 10.20.5 SWOT analysis
  • 10.21 Trinity Biotech
    • 10.21.1 Business overview
    • 10.21.2 Financial data
    • 10.21.3 Product landscape
    • 10.21.4 Strategic outlook
    • 10.21.5 SWOT analysis